retatrutide and breastfeeding Contraindications: Risks Considerations for Patients Retatrutide Peptide While Breastfeeding

While the study did not evaluate GLP-1 ID specifically, it validated the power of Ivms individualized care model

We conducted subgroup analyses based on prespecified risk factors, including age, sex, BMI, degree of liver fibrosis (FIB-4 score 1.3 among patients without cirrhosis), and diabetes severity (diabetes complications)

Sour or sweet smell : Some women report unusual sweet or sour notes due to changes in hydration, infection, or metabolic shifts during midlife

Within six months, his glucose and triglycerides improved

In the same clinical trial, the incidence of constipation was 7% with 1 mg, 6-15% with 4 mg, 6-11% with 8 mg, and 16% with 12 mg dose of retatrutide compared to 3% in the placebo group